Navigation Links
Intra-Cellular Therapies Cleared for Quotation on OTCQB
Date:12/19/2013

allenges for the ongoing development of our product candidates; we may experience difficulties or delays in obtaining regulatory approvals to market products; we may experience difficulties in raising additional capital to pursue our operating plans, which could materially adversely affect our ability to continue as an enterprise; our intellectual property may not provide the protection we require, and we may be subject to third-party intellectual property claims; we may fail to comply with extensive regulatory requirements; we may experience safety issues with ITI-007 or other product candidates that render such potential products of limited value; as well as risks related to key employees, markets, economic conditions, health care reform, prices and reimbursement rates and the other risk factors discussed under the heading "Risk Factors" contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission on October 31, 2013, as well as any updates to those risk factors filed from time to time in our periodic and current reports filed with the Securities and Exchange Commission. The information contained in this press release is believed to be current as of the date of original issue. We do not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in our expectations, except as required by law.

CONTACT:
Allen A. Fienberg, Ph.D.
Vice President
Business Development of Intra-Cellular Therapies, Inc.
+1-212-923-3344

Burns McClellan, Inc.
Lisa Burns/Angeli Kolhatkar (Investors)
Justin Jackson (Media)
jjackson@burnsmc.com
Phone +1 (212) 213-0006


'/>"/>
SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
2. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
3. Immunotherapies Will Continue to Dominate the Malignant Melanoma Drug Market with Sales of Immune Checkpoint Inhibitors Accounting for Majority of Sales in this Drug Class in 2022
4. The Leukemia & Lymphoma Societys (LLS) Greater Bay Area Chapter to Host the 2014 Emerging Therapies & Survivorship Conference
5. Sangamo BioSciences Presents Data From Non-Human Primates Providing Proof Of Concept For Disruptive And Broadly Leverageable Platform For Protein Replacement Therapies
6. Improved Efficacy, Limited Toxicity of Targeted Therapies Brighten the Future of Treatment for Chronic Lymphocytic Leukemia
7. Innovative Compounds, Combination Therapies Improve Care of Patients with Wide Range of Blood Disorders
8. Study Confirms Efficacy of Innovative Therapies Quantum Negative Pressure Wound Therapy (NPWT) in Enhancing Wound Healing
9. Contrasting Reimbursement Environments Result in Different Prescribing Patterns for Premium-Priced Therapies in China and South Korea
10. U.S. Claims Data Show Declining Use of Platform Injectables as Oral Multiple Sclerosis Therapies Gain Traction
11. In the Psoriasis Drug Market, Continued Uptake of Janssens Stelara and the Launch of Emerging Systemic Therapies Will Drive Sales Growth to Nearly $9.2 Billion in 2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... 2014  Training market researchers to spot and ... in today,s highly competitive global marketplace. As resources ... effectively and efficiently produce high performing analysts, regardless ... Effective training programs can help these ... internal clients by developing analysts who can drive ...
(Date:10/17/2014)... -- Research and Markets  has announced the ... of China Dialysis Market, 2014-2018" report to ... 2013 version, this update Report provides detailed analysis ... the relevant effect in recent three years, and ... it analyzes Chinese private-owned hemodialysis services. In the ...
(Date:10/17/2014)... BALTIMORE, Md. , Oct. 17, 2014 /PRNewswire-USNewswire/ ... Center for Medical Technology Policy: The ... from the FDA, public and private payers, medical ... representatives, clinicians, and other experts January 12, 2015 ... effectiveness and value of weight loss treatments.  Participants ...
Breaking Medicine Technology:Effective Training Programs for Market Research Groups can Boost Overall Organizational Success 2Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2
(Date:10/20/2014)... DALLAS (PRWEB) October 20, 2014 It’s hard ... for many orphans and vulnerable children around the world, it’s ... by some people, many children are forced to walk barefoot ... for their families or play with their friends. , ... partnering with Air1 Radio in October to encourage ...
(Date:10/19/2014)... and Hastings, a Phoenix personal injury law firm with ... area and across Arizona reports record demand in 2014 ... Statistics have indicated a steady increase in automobile accidents ... and Hastings has seen a steady increase in the ... injured through no fault of their own that is ...
(Date:10/19/2014)... October 20, 2014 This report ... Partial Seizure, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ... and press releases. It also reviews key players ... and special features on late-stage and discontinued projects. ...
(Date:10/19/2014)... SweetDressy.com, a professional company of women’s dresses and ... evening dresses . All the company’s old and ... discount is up to 66 percent off. , ... fashion field. Its dress specialists are striving to make ... of the world. All the company’s items are unique, ...
(Date:10/19/2014)... spondylitis is a systemic disease that causes inflammation ... have affected members of the ancient Egyptian royal ... Arthritis & Rheumatology , a journal of the ... finding instead a degenerative spinal condition called diffuse ... from the 18th to early 20th Dynasties. ...
Breaking Medicine News(10 mins):Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Mummy remains refute antiquity of ankylosing spondylitis 2
... , , TULSA, Okla., ... its service area across Oklahoma by partnering with several EMS providers ... 1st, 2009. , , Since the commercial ... 1.3 million people served by the Emergency Medical Services Authority (EMSA) ...
... finds more evidence in areas where more men ... -- High levels of persistent environmental chemicals are ... countries with high rates of male reproductive problems, ... endocrine-disrupting chemicals, or EDCs, are commonly found in ...
... , , EMERYVILLE, Calif., Sept. ... today announced that it will webcast an investor briefing on ... Speakers will review clinical data for Nexavar in breast cancer ... European Society for Medical Oncology (ESMO) Multidisciplinary Congress in Berlin. ...
... , LAKE FOREST, Ill., Sept. 24 ... pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of ... Paladin Labs, Inc. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ... to Bioniche,s product offering further broadens our base of niche ...
... introduction of statins to treat high cholesterol, the decline ... double that experienced by the poor. While statins ... health, their use may have contributed to expanding social ... research by Virginia W. Chang, MD, PhD, of the ...
... , , NEW ... market research report is available in its catalogue. , ... Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays ... http://www.reportlinker.com/p0119228/H1N1-(Swine-Influenza)-Market-Assessment-(Latest-Data-Company-Profiles-Implications-for-Immunoassays-and-Molecular-Assays).html , , ...
Cached Medicine News:Health News:Oklahoma Medics Embracing iB Web Service 2Health News:Environmental Chemicals May Affect Male Reproduction 2Health News:Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 2Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 3Health News:Reportlinker Adds H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays) Report 4
Incontinence Pessaries...
Incontinence Dish - Stress Incontinence with mild prolapse. Incontinence Dish with support - Stress Incontinence with mild prolapse and mild cystocele...
... is designed for third degree ... as a cystocele and rectocele. ... both with and without drainage ... tie to aid in removal. ...
... Gellhorn Pessary is used for ... prolapse, or procidentia. It has ... and comes in nine sizes. ... easily folds over for insertion, ...
Medicine Products: